课题基金 / 基金详情

Innovative technology for in vitro evolution of proteins

Innovative technology for in vitro evolution of proteins
蛋白质体外进化的创新技术
批准号:
6484925
负责人:
LIANGJING CHEN CHEN
金额:
$10.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-01 至 2003-04-30

项目摘要

项目成果

LIANGJING CHEN CHEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop a powerful in vitro protein engineering platform that will allow selection or screening of very large numbers of protein variants that is at least 100 -1000 times more cost effective than current 96 well plate based approaches. This strategy is based on generating cell wall bounded micro-compartments, which contain the genetic material, the variant protein and most importantly the product of the enzymatic reaction to allow genotype-phenotype linkage. Using MMLV-reverse transcriptase as a model system, we will develop a novel "permeabilized cell" technology, which is easily adaptable to engineering a broad range of enzymes and proteins and will benefit cancer diagnosis using microarray technology. This technology is a semi in vitro evolution method. The target protein is produced by living cells, which are then permeabilized to allow low molecular weight compounds, such as nucleotides, to diffuse into the cell. The selection step is more like in vitro (within the caged complex formed by the skeleton of fixed cell wall). This technology keeps mutant proteins associated with the DNA encoding them allowing very large numbers of variant proteins to be selected or screened at low cost. PROPOSED COMMERCIAL APPLICATION: Ambion intends to develop an in house protein engineering platform with a novel in vitro evolution methodology. This new technology would provide a powerful tool to evolve proteins with novel functions, such as mutant MMLV-RT and T7 RNA polymerase to incorporate modified nucleotide, which will benefit cancer diagnosis using microarray.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Technologies for Mapping Interspersed AGG Sequences in the FMR1 Gene
  • 批准号:
    8335195
  • 项目类别:
  • 资助金额:
    $61.52万
  • 财政年份:
    2010
  • 负责人:
    LIANGJING CHEN CHEN
  • 依托单位:
Technologies for mapping interspersed AGG sequences in the FMR1 gene
  • 批准号:
    8002575
  • 项目类别:
  • 资助金额:
    $19.22万
  • 财政年份:
    2010
  • 负责人:
    LIANGJING CHEN CHEN
  • 依托单位:
Technologies for Mapping Interspersed AGG Sequences in the FMR1 Gene
  • 批准号:
    8123969
  • 项目类别:
  • 资助金额:
    $70.66万
  • 财政年份:
    2010
  • 负责人:
    LIANGJING CHEN CHEN
  • 依托单位:
Single molecule fluorescence detection of fragile X mutations
  • 批准号:
    7671065
  • 项目类别:
  • 资助金额:
    $32.43万
  • 财政年份:
    2009
  • 负责人:
    LIANGJING CHEN CHEN
  • 依托单位:
国内基金
海外基金
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
  • 批准号:
    32302245
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    潘寒姁
  • 依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
  • 批准号:
    82371775
  • 项目类别:
    面上项目
  • 资助金额:
    46万元
  • 批准年份:
    2023
  • 负责人:
    朱慧媛
  • 依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
  • 批准号:
    31871817
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    孙爱东
  • 依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
  • 批准号:
    81873549
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    刘玉兰
  • 依托单位: